Hongchang International Co., Ltd

HCIL

US42831T2024

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 09:53:06 31/05/2024 pm IST			5-day change	1st Jan Change
0.2001 ^USD	-33.30%		-.--%	-42.63%

15/05	Hongchang International Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/05	Hongchang International Co., Ltd Announces Resignation of Xingjia Gao as a Director from the Board	CI

Heyu Biological Technology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019

March 31, 2020 at 12:05 am IST

Heyu Biological Technology Corporation announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was USD 163,680 compared to USD 0 a year ago. Operating loss was USD 538,124 compared to USD 247,777 a year ago. Net loss was USD 488,386 compared to USD 250,344 a year ago.

Latest news about Hongchang International Co., Ltd

Hongchang International Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Hongchang International Co., Ltd Announces Resignation of Xingjia Gao as a Director from the Board	09/05	CI
Hongchang International Co., Ltd Announces CFO Changes	09/05	CI
Hongchang International Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Hongchang International Co., Ltd Announces Board Changes	02/04	CI
Hongchang International Co., Ltd. has Changed its Ticker to HCIL from HYBT	28/11	CI
Heyu Biological Technology Corporation has Changed its Name to Hongchang International Co., Ltd	22/11	CI
Hongchang International Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Hong Chang Biotechnologies (HK) Limited completed the acquisition of Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction.	04/23/04	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as the Chief Executive Officer	24/23/24	CI
Heyu Biological Technology Corporation Announces Board and Executive Changes	24/23/24	CI
Heyu Biological Technology Corporation Appoints Wendy Wei Li as the Chief Financial Officer of the Company	24/23/24	CI
Hong Chang Biotechnologies (HK) Limited entered into an agreement to acquire Heyu Biological Technology Corporation (OTCPK:HYBT.D) in a reverse merger transaction for HKD 4.4 billion.	23/23/23	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	16/23/16	CI
Insider Buy: Heyu Biological Technology	31/23/31	MT
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	23/23/23	CI
Heyu Biological Technology Corporation Appoints Zengqiang Lin as an Independent Director of the Company	22/23/22	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	13/23/13	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/23/10	CI
Heyu Biological Technology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	24/22/24	CI
Heyu Biological Technology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Heyu Biological Technology Corporation Auditor Raises 'Going Concern' Doubt	01/22/01	CI
Heyu Biological Technology Corporation Appoints Bo Lyu as Chief Financial Officer	30/21/30	CI

Chart Hongchang International Co., Ltd

Duration

Period

More charts

Company Profile

Hongchang International Co Ltd, formerly Heyu Biological Technology Corp, is a holding company mainly engaged in research and development and manufacture a medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the Chamber). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HONGCHANG INTERNATIONAL CO., LTD	-42.63%	156M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B